Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Tuesday, August 12, 2025. The company will host a conference call at 8:30 am ET featuring management discussion of financial results and a business update.
The conference call will be accessible via webcast on Altimmune's Investor Relations website, with dial-in registration available for participants. A replay will be available on the website for up to three months following the call.
Altimmune (NASDAQ:ALT), un'azienda biofarmaceutica in fase clinica avanzata, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per martedì 12 agosto 2025. La società terrà una conference call alle 8:30 ET durante la quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento sul business.
La conference call sarà accessibile tramite webcast sul sito web delle Relazioni con gli Investitori di Altimmune, con registrazione per la partecipazione telefonica. Una registrazione sarà disponibile sul sito per un massimo di tre mesi dopo la chiamata.
Altimmune (NASDAQ:ALT), una compañía biofarmacéutica en etapa clínica avanzada, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el martes 12 de agosto de 2025. La empresa realizará una conferencia telefónica a las 8:30 am ET en la que la dirección discutirá los resultados financieros y proporcionará una actualización del negocio.
La conferencia será accesible vía webcast en el sitio web de Relaciones con Inversores de Altimmune, con registro para participar por teléfono. Una repetición estará disponible en el sitio durante hasta tres meses después de la llamada.
Altimmune (NASDAQ:ALT)는 후기 임상 단계의 바이오제약 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 12일 화요일로 예정했습니다. 회사는 동부 표준시 오전 8시 30분에 경영진이 재무 결과와 사업 현황을 논의하는 컨퍼런스 콜을 진행할 예정입니다.
컨퍼런스 콜은 Altimmune 투자자 관계 웹사이트를 통해 웹캐스트로 접속할 수 있으며, 참가자들은 전화 등록도 할 수 있습니다. 콜 종료 후 최대 3개월간 웹사이트에서 다시 듣기가 가능합니다.
Altimmune (NASDAQ:ALT), une société biopharmaceutique en phase clinique avancée, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le mardi 12 août 2025. La société tiendra une conférence téléphonique à 8h30 ET au cours de laquelle la direction discutera des résultats financiers et fera une mise à jour commerciale.
La conférence téléphonique sera accessible via webcast sur le site des relations investisseurs d'Altimmune, avec une inscription téléphonique disponible pour les participants. Un replay sera disponible sur le site pendant trois mois après l'appel.
Altimmune (NASDAQ:ALT), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Dienstag, den 12. August 2025 geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz veranstalten, in der das Management die Finanzergebnisse und ein Geschäftsupdate besprechen wird.
Die Telefonkonferenz ist per Webcast auf der Investor-Relations-Website von Altimmune zugänglich, eine telefonische Registrierung für Teilnehmer ist möglich. Eine Aufzeichnung wird bis zu drei Monate nach der Konferenz auf der Website verfügbar sein.
- None.
- None.
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025.
Altimmune management will host a conference call at 8:30 am E.T. on August 12 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke, Biotech
Phone: 619-849-5383
Jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) report Q2 2025 earnings?
What time is Altimmune's Q2 2025 earnings call?
How can investors access Altimmune's Q2 2025 earnings call?
How long will Altimmune's Q2 2025 earnings call replay be available?
